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Is there still a place for improvement in
acute coronary syndrome risk
stratiﬁcation?
Ana Teresa Timóteo
In ST-elevation myocardial infarction
(STEMI), early diagnosis by the speciﬁc
ECG changes and timely reperfusion
therapy, has remarkably improved the
outcome. The non-ST-elevation acute cor-
onary syndrome (NSTEACS) cohort is
usually larger and more heterogeneous.
Given the wide spectrum of antithrombo-
tic and antiplatelet therapies available
today, as well as improvements in invasive
management, it requires a timely manage-
ment decision by physicians. Although
these therapeutic options improve
outcome, they can increase both the rate
of complications and costs. For that re-
ason, an informed decision is important
and risk stratiﬁcation scores are helpful
tools for an early triage and adequate
identiﬁcation of intermediate/high-risk
groups that can beneﬁt from an invasive
strategy.
In the last 15 years, several risk stratiﬁ-
cation scores for acute coronary syn-
dromes (ACSs) have been developed. The
ﬁrst risk scores to be widely implemented
in clinical practice were Thrombolysis
in Myocardial Infarction risk score for
STEMI and NSTEACS.1 2 These scores
were developed from cohorts of patients
included in randomised clinical trials.
Subsequent risk scores used the same
methodology. Global Registry of Acute
Coronary Events (GRACE) risk score was
published in 2003 by the GRACE registry
group, initially for hospital mortality in
patients with ACS and later on for
6-month mortality.3 4 This score was
developed from a registry that represents
real-world patients instead of the highly
controlled and selected population found
in clinical trials, which is considered a
limitation of previous risk scores. Elderly
patients and patients with severe renal
dysfunction are usually excluded from
clinical trials. This might explain the
inclusion of new variables such as renal
function in the new real-life score.
Nowadays, due to its high predictive
accuracy for both short-term and
medium-term all-cause mortality, it is the
most widely used risk score in ACS
context. Since then, many authors have
shown the incremental prognostic value
of other clinical and laboratorial variables
on top of GRACE risk score.
Patients with chronic obstructive pul-
monary disease (COPD) are at high-risk
of experiencing ACS.5 This risk is usually
attributed to common risk factors, such
as higher age and smoking, as well as
to the systemic inﬂammatory response
present in COPD.6 A patient with COPD
experiencing ACS have a subsequent in-
creased risk of recurrent ischaemic events
and long-term all-cause mortality, ex-
plained by the fact that they have higher
prevalence of age-related and smoking-
related comorbidities and are less likely to
receive invasive treatment and guideline-
recommended secondary prevention ther-
apies, including a lower likelihood of
cardiac rehabilitation attendance after
myocardial infarction.5 The association
with prolonged hypoxaemia and the use
of inhaled β-agonists among patients with
COPD could also contribute to the ele-
vated arrhythmic risk, which potentially
may also inﬂuence inhospital outcome.6
Also in patients that survive to discharge
after and ACS, COPD has an important
long-term prognostic impact. The long-
tErm follow-up of antithrombotic man-
agement Patterns In acute CORonary
syndrome patients (EPICOR) study
showed that COPD is present in 6% of
the patients that survived to hospital dis-
charge after ACS and it is an independent
predictor of all-cause 1-year mortality
with a crude mortality rate of 8.8%.
However, the impact is only signiﬁcant in
the NSTEACS cohort.7
In their Heart publication, Rothnie et al
report on the prognostic utility of COPD
in a sample of 481 849 patients with ACS
admitted to UK hospitals in England and
Wales and included in the myocardial
ischaemia national audit project (MINAP)
database. The authors compared the risk
of death between patients with COPD
and non-COPD at 6 months and they
further assessed the incremental prognos-
tic value when associated to GRACE risk
score. COPD was present in 12.2% of
patients with ACS and they had a 30%
higher risk of death, even after adjustment
for GRACE risk score. As in previous
observational studies, they have a particu-
larly high-risk proﬁle, including higher
age, high prevalence of chronic heart
failure, coronary artery disease, cerebro-
vascular disease, peripheral artery disease
and chronic renal disease. Inclusion of
COPD in the GRACE score equation, or
multiplying the GRACE predicted risk of
death by 1.3 for people with COPD
were the two strategies proposed by the
authors for improved outcome prediction.
Approximately, one-third of patients with
COPD categorised as low risk, are in fact
moderate risk patients.
The association observed with all-cause
mortality does not automatically mean
that adding COPD as a new marker to a
traditional risk prediction model will
improve outcome risk prediction.
Discriminative analysis of a model with
GRACE risk score alone and after adjust-
ment for COPD showed that c-statistic
increased very slightly, although signiﬁ-
cantly. In the quantiﬁcation of correct
reclassiﬁcation, COPD adjustment of a
model with GRACE score was associated
with an Net Reclassiﬁcation Index (NRI)
of 13%, suggesting effective reclassiﬁca-
tion with similar results in different types
of ACS. The magnitude of improvement
was small, which was expected in the
presence of a fairly robust risk score, such
as in the case of GRACE risk score. In
smaller sample populations, it might not
be the case, because signiﬁcance was
attainable due to the very large sample.
The main strength of the present study
is the very large sample size, obtained
from a nationwide multicenter registry.
The most important limitation is that
COPD was diagnosed based on local
physician assessment only. Pulmonary
function tests were not routinely per-
formed to diagnose and quantify COPD
severity. Most studies on COPD and ACS
used a clinical deﬁnition based in a previ-
ous history of COPD treated with
pharmacological therapies for obstructive
lung disease (inhaled steroids, inhaled
anticholinergics, inhaled β-agonists theo-
phylline) at hospital admission. This may
lead to underestimation or misdiagnosis
of COPD frequency. Previous studies
reported very different prevalence’s of
COPD, ranging from 5.8% to 18.2%
(table 1). A study with spirometry screen-
ing in patients with ACS obtained an
objective COPD prevalence up to 11%,
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when only 5% were positive by medical
record review only.8 Another possible
limitation for the results presented is
related to data analysis. COPD and Killip
class were not reported in MINAP data-
base and the authors used surrogate
markers to identify those patients. The
National Institute for Health and Care
Excellence amended mini-GRACE score
was used instead. Although both methods
were previously validated, nonetheless this
is a cause for some possible bias.
However, one of the main questions is
the real-beneﬁt of including all those new
prognostic variables in GRACE risk score.
GRACE risk score nomogram includes
several variables with a wide range of cat-
egories, adding some complexity to risk
scoring. This might explain its underuse
in clinical practice in spite of the dev-
elopment of several tools including
internet-based calculators, also for mobile
devices.10 Inclusion of other variables can
increase complexity even further and
compromise its use. Previous studies
showed that it is possibly to simplify risk
scores with simple and fewer variables,
with similar predictive accuracy. The
Canada Acute Coronary Syndrome risk
score selected simple variables (age, Killip
class, systolic blood pressure and heart
rate) and it allows rapid stratiﬁcation of
patients with ACS including by healthcare
professionals without advanced medical
training at the prehospital setting or emer-
gency department.11 It showed a good
predictive value both for short-term and
long-term mortality and in both STEMI
and NSTEACS, although slightly lower
when compared with classical risk scores.
Maybe a strategy of early and simple risk
stratiﬁcation would be more appropriate
with subsequent stratiﬁcation considering
all additional prognostic comorbidities
identiﬁed so far, such as diabetes, renal
function and COPD. In STEMI immedi-
ate reperfusion therapy is essential and
risk stratiﬁcation is less important. In
NSTEACS, invasive treatment has a wide
range of option, between immediate and
72 hours delay. Immediate invasive treat-
ment can be selected by very simple clin-
ical assessment and it does not require
risk scoring. For other strategies, we have
more time to consider the prognostic
impact of other comorbidities. It is thus
necessary to understand in real-life clinical
practice, what is the real-impact of risk
scoring, both in terms of use and in terms
of management implications.
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Table 1 Reported prevalence of COPD in myocardial infarction patients
Author Country/study Prevalence (%) Observations
Salisbury et al12 USA (PREMIER study) 15.6 Discharged alive
Dziewierz et al6 Poland (registry) 11.3
Hadi et al13 Middle East (GULF RACE) 5.3
Bursi et al14 USA 12.0
Stefan et al15 USA 17.0
Campo et al16 Italy 18.2
Andell et al17 Sweden (Registry) 6.0
Andell et al18 International (PLATO trial) 5.8
Pocock et al7 International (EPICOR study) 6.4 Discharged alive
COPD, chronic obstructive pulmonary disease; EPICOR, tErm follow-up of antithrombotic management Patterns In acute
CORonary syndrome patients; PLATO, platelet inhibition and patient outcome; PREMIER, prospective registry evaluating
myocardial infarction: events and recovery.
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